Possibilities of new therapeutic strategies in brain tumors

2010 ◽  
Vol 36 (4) ◽  
pp. 335-341 ◽  
Author(s):  
Eric Bouffet ◽  
Uri Tabori ◽  
Annie Huang ◽  
Ute Bartels
Keyword(s):  
Brain Tumors ◽  
Therapeutic Strategies

Combinatorial Therapeutic Strategies for Blocking Kinase Pathways in Brain Tumors

CNS Cancer ◽  
2009 ◽  
pp. 953-975
Author(s):  
Paul H. Huang ◽  
Forest M. White
Keyword(s):  
Brain Tumors ◽  
Therapeutic Strategies

scholarly journals P13.14 Use of Foundation one CDx for molecular screening in patients with primary brain tumors: Gustave Roussy Experience

2019 ◽  
Vol 21 (Supplement_3) ◽  
pp. iii65-iii65
Author(s):  
C Baldini ◽  
W Boulfoul ◽  
L Lacroix ◽  
E Rouleau ◽  
J Scoazec ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Brain Tumors ◽  
Tumor Tissue ◽  
Therapeutic Strategies ◽  
Braf V600e ◽  
Tumor Type ◽  
Molecular Screening ◽  
Primary Brain Tumors ◽  
Molecular Alterations ◽  
Multidisciplinary Meeting

Abstract BACKGROUND Patients with primary brain tumors usually have poor prognosis and few therapeutic options. However recent report showed that they may benefit from molecular screening to improve treatment benefit and enrollment in clinical trials. We aimed to evaluate if molecular screening using Foundation One Dx may help therapeutic strategies in primary brain tumor patients. MATERIAL AND METHODS Between October 2018 and December 2018, we enrolled prospectively patients in the MOSCATO (Molecular Screening for cancer Treatment Optimization) 02 trial using the Foundation One Dx test. Patients were eligible if they had good Performans status (PS) (0 or 1) and tumor tissue material available. Results were reviewed during a molecular multidisciplinary meeting weekly at the Drug Development Department at Gustave Roussy to decide on orientation and matched therapy according to molecular alterations. RESULTS Finally thirty-three patients were enrolled in the study. Twenty six tumor tissues were analysed and 7 patients were screen failures due to tumor tissue unavailability. Median age was 49 years old (19 - 72). Patients had a good PS with a median of 1 (0–2) and were mostly males (76%). The most common tumor type was glioblastoma (79%). Five patients had a high grade tumor including 2 medulloblastomas. Median time between consent and multidisciplinary meeting was 70 days (49 - 156). Median percentage of tumor cells was 78% (30–80%). The tumor mutational burden (TMB) was available in 26 patients. The median TMB was 4 mutations per megabase (0 - 277). The most frequent alterations were TERT promoter mutation 22/26 (85%), CDKN2A loss 14/26 (54%), MTAP loss 11/26 (42%), EGFR amplification (38%) including 4 EGFRvIII amplification, TP53 mutation and PTEN deletion 9/26 (35%) respectively, PIK3CA mutation 5/26 (19%), CDK4 or 6 amplification 4/26 (15%), NF1 mutation 3/26 (12%), 2 IDH1 mutations, 2 MET amplifications, 2 HGF amplifications, 1 FGFR2 mutation, 1 BRAF V600E mutation, 1 PDGFRA amplification, 1 EZH2 mutation and 1 SMARCA4 mutation. Finally 11 patients (42%) were oriented according to molecular alterations (EGFR amplifications, BRAF mutation), 1 patient was treated and is ongoing with a BRAF inhibitor and 1 patient is in screening in atrial with an EGFR inhibitor. CONCLUSION Molecular screening with Foundation One Dx test is feasible in patients with primary brain tumors and can help therapeutic strategies. However the time between consent and multidisciplinary meeting was the main limitation to our study and affected enrollment in clinical trials.

scholarly journals Infantile Brain Tumors: A Review of Literature and Future Perspectives

Diagnostics ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. 670
Author(s):  
Valeria Simone ◽  
Daniela Rizzo ◽  
Alessandro Cocciolo ◽  
Anna Maria Caroleo ◽  
Andrea Carai ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Therapeutic Strategies ◽  
Clinical Applications ◽  
Review Of Literature ◽  
Future Perspectives ◽  
Older Children ◽  
Nervous System Tumors ◽  
Molecular Landscape ◽  
Specific Symptoms

Brain tumors in infants including those diagnosed in fetal age, newborns and under a year old represent less than 10% of pediatric nervous system tumors and present differently when compared with older children in terms of clinical traits, location and histology. The most frequent clinical finding is a macrocephaly but non-specific symptoms can also be associated. The prognosis is usually poor and depends on several factors. Surgery continues to be the main option in terms of therapeutic strategies whereas the role of chemotherapy is not yet well defined and radiotherapy is exceptionally undertaken. In view of this situation, a molecular characterization could assist in providing therapeutic options for these tumors. This review highlights the recent advances in the diagnosis and treatment of brain tumors in infants with a particular focus on the molecular landscape and future clinical applications.

scholarly journals Blood Brain Barrier: A Challenge for Effectual Therapy of Brain Tumors

2015 ◽  
Vol 2015 ◽  
pp. 1-20 ◽  
Author(s):  
Arijit Bhowmik ◽  
Rajni Khan ◽  
Mrinal Kanti Ghosh
Keyword(s):  
Brain Tumors ◽  
Blood Brain Barrier ◽  
Therapeutic Strategies ◽  
Brain Barrier ◽  
Transport Systems ◽  
High Relapse Rate ◽  
Blood Brain ◽  
Novel Therapeutic Strategies ◽  
And Function ◽  
Molecular Components

Brain tumors are one of the most formidable diseases of mankind. They have only a fair to poor prognosis and high relapse rate. One of the major causes of extreme difficulty in brain tumor treatment is the presence of blood brain barrier (BBB). BBB comprises different molecular components and transport systems, which in turn create efflux machinery or hindrance for the entry of several drugs in brain. Thus, along with the conventional techniques, successful modification of drug delivery and novel therapeutic strategies are needed to overcome this obstacle for treatment of brain tumors. In this review, we have elucidated some critical insights into the composition and function of BBB and along with it we have discussed the effective methods for delivery of drugs to the brain and therapeutic strategies overcoming the barrier.

Role of quality of life in therapeutic strategies in brain tumors

Health Policy ◽  
1988 ◽  
Vol 10 (3) ◽  
pp. 241-257 ◽  
Author(s):  
Pirjo Koivukangas ◽  
John Koivukangas
Keyword(s):  
Quality Of Life ◽  
Brain Tumors ◽  
Therapeutic Strategies

scholarly journals TMOD-29. ESTABLISHMENT OF PATIENT-DERIVED XENOGRAFTS FROM RARE PRIMARY BRAIN TUMORS

2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii234-ii234
Author(s):  
Noriyuki Kijima ◽  
Yoshikazu Nakajima ◽  
Daisuke Kanematsu ◽  
Tomoko Shofuda ◽  
Yuichiro Higuchi ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Translational Research ◽  
Single Cells ◽  
Molecular Classification ◽  
Therapeutic Strategies ◽  
Molecular Characteristics ◽  
Preclinical Development ◽  
Primary Brain Tumors ◽  
Novel Therapeutic Strategies ◽  
Novel Therapeutic

Abstract Patient derived xenografts are essential tools for translational research and preclinical development of novel therapeutic strategies of primary brain tumors. Recent advances in genomics of primary brain tumors revealed molecular classification of primary brain tumors, thus establishment of patient derived xenografts from each subtype of primary brain tumors is urgently needed. However, currently available patient derived xenografts are limited and are from specific subtype of primary brain tumors such as glioblastoma IDH wild type. In this study, we aim to establish patient derived xenografts from primary brain tumors with various molecular characteristics, especially rare primary brain tumors. We got primary brain tumor tissues from patients, dissociated those tissue into single cells, and orthotopically injected those cells into NOD/Shi-scid IL2Rγ KO mouse. We successfully established rare patient-derived xenografts from atypical teratoid rhabdoid tumor and CNS Ewing sarcoma family tumor with CIC alteration, which is recently described as new entity of primitive neuroectodermal tumors of the CNS. We also analyzed histopathological characteristics of these xenografts and found that each xenograft well recapitulated histopathological features of original patients’ resected tumors. These xenografts have advantages for translational research and preclinical development of novel therapeutic strategies for rare primary brain tumors. In addition, further efforts are needed to establish other types of rare primary brain tumors.

Sign in / Sign up

Export Citation Format

Share Document